Gabapentin treatment for muscle cramps: an open-label trial.

abstract：:Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients...

journal_title：Clinical neuropharmacology

authors： Obeso JA,Artieda J,Quinn N,Rothwell JC,Luquin MR,Vaamonde J,Marsden CD

更新日期：1988-12-01 00:00:00

abstract：:The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

更新日期：1994-02-01 00:00:00

abstract：:Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study w...

journal_title：Clinical neuropharmacology

authors： Bagheri H,Damase-Michel C,Lapeyre-Mestre M,Cismondo S,O'Connell D,Senard JM,Rascol O,Montastruc JL

更新日期：1999-07-01 00:00:00

abstract：OBJECTIVE:Use of antipsychotic agents in the management of various psychopathologies in Child and Adolescent Psychiatric practice is gradually increasing. This study aimed to evaluate the sociodemographic and clinical features of children and adolescents who applied to an outpatient clinic of child and adolescent psych...

journal_title：Clinical neuropharmacology

authors： Yektaş Ç,Tufan AE

更新日期：2018-01-01 00:00:00

abstract：:Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently appr...

journal_title：Clinical neuropharmacology

authors： Richard IH,Justus AW,Greig NH,Marshall F,Kurlan R

更新日期：2002-11-01 00:00:00

abstract：BACKGROUND:Introduction of old and new generations of antipsychotics leads to significant improvements in the positive symptoms of schizophrenia. However, negative symptoms remain refractory to conventional trials of antipsychotic therapy. Recently, there were several open clinical human trials with curcumin. Curcumin ...

journal_title：Clinical neuropharmacology

authors： Miodownik C,Lerner V,Kudkaeva N,Lerner PP,Pashinian A,Bersudsky Y,Eliyahu R,Kreinin A,Bergman J

更新日期：2019-07-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to report the case of a male patient with Parkinson disease who developed brachial plexopathy (BP) due to varicella-zoster virus, which was successfully treated with human immunoglobulin. METHOD:We report the case of a 75-year-old male subject with a diagnosis of Parkinson disease w...

journal_title：Clinical neuropharmacology

authors： Sáenz-Farret M,Sandoval-Rodríguez V,Paz-Navarro CE,Zúñiga-Ramírez C

更新日期：2017-01-01 00:00:00

abstract：:We investigated genetic polymorphism of the cytochrome P-450 CYP2D6 gene from white patients with idiopathic Parkinson's disease (IPD). The mutations of the CYP2D6 gene associated with the poor metabolizer (PM) phenotype of the debrisoquine/sparteine polymorphism were analyzed in DNA of 130 IPD patients by a polymeras...

journal_title：Clinical neuropharmacology

authors： Bordet R,Broly F,Destée A,Libersa C,Lafitte JJ

更新日期：1996-06-01 00:00:00

abstract：:In this report, we present a patient whose positive symptoms did not improve despite being treated with clozapine monotherapy at a therapeutic dose for 4 months, and whose symptoms began to resolve after aripiprazole long-acting injection adjunction to clozapine. A 22-year-old man was diagnosed as having schizophrenia...

journal_title：Clinical neuropharmacology

authors： Balcioglu YH,Gokcay H,Yesilkaya UH

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Serotonin syndrome is a potentially fatal complication that usually occurs in the combination use of several serotonergic agents. We presented a patient with major depressive disorder under the treatment of bupropion, trazodone, and quetiapine. Serotonin syndrome developed soon after she received the first s...

journal_title：Clinical neuropharmacology

authors： Cheng YC,Liang CM,Liu HC

更新日期：2015-05-01 00:00:00

abstract：:The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...

journal_title：Clinical neuropharmacology

authors： da Rocha FF,Correa H

更新日期：2011-07-01 00:00:00

abstract：OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

journal_title：Clinical neuropharmacology

authors： Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

更新日期：2017-11-01 00:00:00

abstract：:Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomo...

journal_title：Clinical neuropharmacology

authors： Pirtosek Z,Merello M,Carlsson A,Stern G

更新日期：1993-12-01 00:00:00

abstract：:Two patients with essential tremor who had no psychiatric history developed symptoms of psychosis (visual hallucinations, paranoia, and vivid dreams) 3 days after starting topiramate (25 mg BID) for tremor control. All adverse symptoms resolved several days after topiramate was discontinued. ...

journal_title：Clinical neuropharmacology

authors： Zesiewicz TA,Tullidge A,Tidwell J,Sullivan KL,Hauser RA

更新日期：2006-05-01 00:00:00

abstract：OBJECTIVE:Psychogenic polydipsia occurs frequently in patients with chronic psychiatric illness and is often unmanageable. We herein report 5 patients in whom acetazolamide was trialed for this symptom. METHODS:We encountered a case in which polydipsia improved with incidental administration of acetazolamide. We then ...

journal_title：Clinical neuropharmacology

authors： Takagi S,Watanabe Y,Imaoka T,Sakata M,Watanabe M

更新日期：2011-01-01 00:00:00

abstract：:The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

journal_title：Clinical neuropharmacology

authors： Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

更新日期：2005-05-01 00:00:00

abstract：:Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

journal_title：Clinical neuropharmacology

authors： Klawans HL,Tanner CM,Barr A

更新日期：1984-01-01 00:00:00

abstract：:A correlation was found among the degree of memory loss, intellectual impairment, the quantity of senile plaques, and a decrease in choline acetyltransferase and acetylcholinesterase activity in patients affected by senile dementia of the Alzheimer type. In this study, patients were subjected to a series of computeriz...

journal_title：Clinical neuropharmacology

authors： Agnoli A,Martucci N,Manna V,Conti L,Fioravanti M

更新日期：1983-01-01 00:00:00

abstract：:Transient global amnesia (TGA) has been proposed as a possible adverse effect of sildenafil. There are rare cases in the literature, but none had strong evidence to support. Our case is the first to demonstrate a focal punctate diffusion-weighted imaging lesion at the right hippocampus after the use of sildenafil. Thi...

journal_title：Clinical neuropharmacology

authors： Lin KY,Liu MN,Wang PH,Lau CI

更新日期：2020-03-01 00:00:00

abstract：:Despite ongoing dispute over the pathophysiologic basis of migraine, the vasospastic theory of pathogenesis has brought to the forefront a promising class of new antimigraine agents, the Ca2+ channel antagonists. Voltage-dependent Ca2+ channels, integral membrane proteins that permit extracellular Ca2+ to enter cells ...

journal_title：Clinical neuropharmacology

authors： Greenberg DA

更新日期：1986-01-01 00:00:00

abstract：:Aminopyridines are members of a family of monoamino and diamino derivatives of pyridine, and their principal mechanism of action is dose-dependent blockade of voltage-gated potassium channels, in particular, fast voltage-gated potassium channels. To date, only 2 main broad-spectrum potassium channel blockers, 4-aminop...

journal_title：Clinical neuropharmacology

authors： Sedehizadeh S,Keogh M,Maddison P

更新日期：2012-07-01 00:00:00

abstract：OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...

journal_title：Clinical neuropharmacology

authors： Takahashi H,Oshimo T,Ishigooka J

更新日期：2009-05-01 00:00:00

abstract：:Interferons are a set of cytokines that activate antiviral responses by the body's immune cells and have been a mainstay of treatment of hepatitis C. Well-known neuropsychiatric effects of interferons include depression, irritability, and impaired concentration. A condition reported rarely in association with this tre...

journal_title：Clinical neuropharmacology

authors： Wangensteen KJ,Krawitt EL,Hamill RW,Boyd JT

更新日期：2016-01-01 00:00:00

abstract：:Obsessive-compulsive disorder (OCD) is a brain disorder with recognizable periods of onset, course, familial occurrence, epidemiology, phenomenology, and treatment response. Several manifestations of pathophysiology are beginning to be defined, although they may represent intermediate pathophysiology rather than prima...

journal_title：Clinical neuropharmacology

authors： Micallef J,Blin O

更新日期：2001-07-01 00:00:00

abstract：:A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

journal_title：Clinical neuropharmacology

authors： Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

更新日期：2008-05-01 00:00:00

abstract：:Recent studies have suggested that deprenyl may exert a neuroprotective influence and thus retard progression of Parkinson's disease (PD). On the other hand, the data do not disprove that deprenyl is primarily another form of symptomatic therapy like levodopa. Longitudinal Gompertzian analysis demonstrates the absence...

journal_title：Clinical neuropharmacology

authors： Riggs JE

更新日期：1991-12-01 00:00:00

abstract：BACKGROUND:Topiramate (TPM) is a fructose derivative, which was originally developed as an antiepileptic. In this context, movement disorders (MDs) are possible adverse events secondary to TPM. CASE REPORTS:Two patients (cases 1 and 2) developed myoclonus, and the other 2 had restless leg syndrome (RLS, cases 3 and 4)...

journal_title：Clinical neuropharmacology

authors： Rissardo JP,Caprara ALF

更新日期：2020-07-01 00:00:00

abstract：:The authors compared the two portions of the OFF period in patients with Parkinson disease and response fluctuations: time to ON (the latency from levodopa intake to turning ON) and wearing off (time from termination of the beneficial dose effect until the time when the next dose was taken). Time to ON was more than t...

journal_title：Clinical neuropharmacology

authors： Merims D,Djaldetti R,Melamed E

更新日期：2003-07-01 00:00:00

abstract：:A patient with melanoma and sporadic positive melanuria developed Parkinson's disease. Treatment with levodopa failed to modify tumoral progress. However, during chemotherapy with dacarbazine, the patient experienced a significant impairment to levodopa response. ...

journal_title：Clinical neuropharmacology

authors： Merello M,Esteguy M,Perazzo F,Leiguarda R

更新日期：1992-02-01 00:00:00

abstract：:The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...

journal_title：Clinical neuropharmacology

authors： Bonuccelli U,Murialdo G,Martino E,Lecchini S,Bonura ML,Bambini G,Murri L

更新日期：1985-01-01 00:00:00